Replies to post #13018 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Do you think the market has discounted Baxter's option for the 3 molecules or we are looking at further price weakness?

I would say the market expects BAX to not opt in for more FoBs; hence, if BAX does opt in, the news will be favorably viewed, and if BAX does not opt in, it will be largely ignored. JMHO, FWIW